Ten-Year Data for Merck's KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall ...
10-year follow-up data from KEYNOTE-006 trial shows 34.0% of advanced melanoma patients treated with KEYTRUDA were alive, compared to 23.6% with ipilimumab. KEYTRUDA demonstrated sustained OS benefits, reducing death risk by 29%.
Related Clinical Trials
Reference News
Merck’s Keytruda (pembrolizumab) showed superior 10-year overall survival (OS) over Yervoy (ipilimumab) in advanced melanoma patients, with a 34% OS rate for Keytruda versus 23.6% for Yervoy, reducing death risk by 29%. Keytruda’s median OS was 32.7 months, more than double Yervoy’s 15.9 months. Keytruda has transformed melanoma treatment and extended benefits to other cancers.
10-year follow-up data from KEYNOTE-006 trial shows 34.0% of advanced melanoma patients treated with KEYTRUDA were alive, compared to 23.6% with ipilimumab. KEYTRUDA demonstrated sustained OS benefits, reducing death risk by 29%.
Pembrolizumab (Keytruda) continued to show superior survival outcomes over ipilimumab (Yervoy) in patients with unresectable advanced melanoma, according to 10-year follow-up data from the phase 3 KEYNOTE-006 study. The median overall survival was 32.7 months with pembrolizumab vs 15.9 months with ipilimumab, with 8- and 10-year OS rates of 36.9% and 34.0% vs 24.8% and 23.6%, respectively. The study also highlighted the long-term benefits of pembrolizumab in various patient subgroups, reinforcing its standard of care status in advanced melanoma treatment.